Savara shares fell 16% in premarket trading on Friday after the United States Food and Drug Administration missed its November 22 deadline to decide on the company's rare lung disease treatment. The missed decision delivers a setback to the biotech firm as it awaits word on its experimental drug. Investors face an extended wait for regulatory clarity with no new decision date provided.
FDA Misses Deadline for Savara Drug
Savara shares fell after the US FDA missed its deadline to decide on the approval of its rare lung disease treatment. The application for molgramostim remains under review without a new decision date.
Insights:








